Here's the secret behind CSL's monster 42% return on equity

Breaking down CSL Limited's (ASX:CSL) monster returns on equity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last week I noted that blood product company CSL Limited (ASX: CSL) was building up a steady history of monster returns on equity (roe).

At 42% these returns are far above the 6% industry average hinting at a company with a strong, sustainable competitive advantage. But where is the high return coming from?

Breaking down return on equity

To see where CSL's huge 42% ROE comes from, we can break it out into three components using a method called DuPont analysis:

  • Net profit margin (Net Income ÷ Revenue) 0.22
  • Asset Turnover (Revenue ÷ Assets) 0.73
  • Equity Multiplier (Assets ÷ Shareholders' Equity) 2.64
  • Return on equity = (0.22) x (0.73) x (2.64) = 42%

Even by healthcare standards CSL's 42% ROE is impressive, with Cochlear Limited (ASX: COH) being one of the few companies to come close at 40%.

But when we break it down we can see that the big driver of the returns is in fact CSL's use of debt to fund assets; the high equity multiplier. Without this, if CSL didn't leverage its assets with borrowed money, ROE would only be 16%.

Why does CSL use debt, rather than fund growth from its strong cash flows? With borrowing costs so low it makes sense to use debt to fund moderate growth if the company knows it can generate new income above it's average cost of capital to pay it back.

CSL has strong cash flows to service its interest payments, but if a comparable investment had a higher unleveraged return, we may prefer to buy it.

Foolish takeaway

To me, CSL is to healthcare what Johnson & Johnson is to consumer products, or what Nestlé is to snack foods; a well-structured staple producer with low cyclical volatility and strong margins and volumes.

It's a company I would still love to own, and I will certainly be watching for any weakness in share price.

Motley Fool contributor Regan Pearson has no position in any of the stocks mentioned. You can follow him on Twitter @Regan_Invests. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »